nach oben

Erschienen in:

19.10.2015 | Original Article

Downregulation of lncRNA-ATB correlates with clinical progression and unfavorable prognosis in pancreatic cancer

verfasst von: Shibin Qu, Xisheng Yang, Wenjie Song, Wei Sun, Xiaolei Li, Jianlin Wang, Yue Zhong, Runze Shang, Bai Ruan, Zhuochao Zhang, Xuan Zhang, Haimin Li

Erschienen in: Tumor Biology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Long noncoding RNAs (lncRNAs) have been shown to play critical roles in the development and progression of diseases. lncRNA activated by transforming growth factor beta (TGF-β) (lncRNA-ATB) was discovered as a prognostic factor in hepatocellular carcinoma, gastric cancer, and colorectal cancer. However, little is known about the role of lncRNA-ATB in pancreatic cancer. This study aimed to assess lncRNA-ATB expression in pancreatic cancer and explore its role in pancreatic cancer pathogenesis. Quantitative real-time polymerase chain reaction was performed to detect lncRNA-ATB expression in 150 pancreatic cancer tissues and five pancreatic cancer cell lines compared to paired adjacent normal tissues and normal human pancreatic ductal epithelial cell line HPDE6c-7. The correlations between lncRNA-ATB expression and clinicopathological characteristics and prognosis were also analyzed. We found that lncRNA-ATB expression was decreased in pancreatic cancer tissues and pancreatic cancer cell lines. Low lncRNA-ATB expression levels were significantly correlated with lymph node metastases (yes vs. no, P = 0.009), neural invasion (positive vs. negative, P = 0.049), and clinical stage (early stage vs. advanced stage, P = 0.014). Moreover, patients with low lncRNA-ATB expression levels exhibited markedly worse overall survival prognoses (P < 0.001). Multivariate analysis indicated that decreased lncRNA-ATB expression was an independent predictor of poor prognosis in pancreatic cancer patients (P = 0.005). In conclusion, lncRNA-ATB may play a critical role in pancreatic cancer progression and prognosis and may serve as a potential prognostic biomarker in pancreatic cancer patients.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. doi:10.3322/caac.21254.CrossRefPubMed

Ryan DP, Hong TS, Bardeesy N. N Engl J Med. 2014;371(22):2140–1. doi:10.1056/NEJMc1412266.PubMed

Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378(9791):607–20. doi:10.1016/S0140-6736(10)62307-0.CrossRefPubMedPubMedCentral

Hartwig W, Werner J, Jäger D, Debus J, Büchler MW. Improvement of surgical results for pancreatic cancer. Lancet Oncol. 2013;14(11):e476–85. doi:10.1016/S1470-2045(13)70172-4.CrossRefPubMed

Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136(4):629–41. doi:10.1016/j.cell.2009.02.006.CrossRefPubMed

Shi X, Sun M, Liu H, Yao Y, Song Y. Long non-coding RNAs: a new frontier in the study of human diseases. Cancer Lett. 2013;339(2):159–66. doi:10.1016/j.canlet.2013.06.013.CrossRefPubMed

Xu SP, Zhang JF, Sui SY, Bai NX, Gao S, Zhang GW, et al. Down regulation of the long noncoding RNA EGOT correlates with malignant status and poor prognosis in breast cancer. Tumour Biol. 2015. doi:10.1007/s13277-015-3746-y.

Huarte M, Rinn JL. Large non-coding RNAs: missing links in cancer? Hum Mol Genet. 2010;19(R2):R152–61. doi:10.1093/hmg/ddq353.CrossRefPubMedPubMedCentral

Li J, Liu D, Hua R, Zhang J, Liu W, Huo Y, et al. Long non-coding RNAs expressed in pancreatic ductal adenocarcinoma and lncRNA BC008363 an independent prognostic factor in PDAC. Pancreatology. 2014;14(5):385–90. doi:10.1016/j.pan.2014.07.013.CrossRefPubMed

10.

Sun YW, Chen YF, Li J, Huo YM, Liu DJ, Hua R, et al. A novel long non-coding RNA ENST00000480739 suppresses tumour cell invasion by regulating OS-9 and HIF-1α in pancreatic ductal adenocarcinoma. Br J Cancer. 2014;111(11):2131–41. doi:10.1038/bjc.2014.520.CrossRefPubMedPubMedCentral

11.

Ma C, Nong K, Zhu H, Wang W, Huang X, Yuan Z, et al. H19 promotes pancreatic cancer metastasis by derepressing let-7’s suppression on its target HMGA2-mediated EMT. Tumour Biol. 2014;35(9):9163–9. doi:10.1007/s13277-014-2185-5.CrossRefPubMed

12.

Kim K, Jutooru I, Chadalapaka G, Johnson G, Frank J, Burghardt R, et al. HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene. 2013;32(13):1616–25. doi:10.1038/onc.2012.193.CrossRefPubMed

13.

Jiao F, Hu H, Yuan C, Wang L, Jiang W, Jin Z, et al. Elevated expression level of long noncoding RNA MALAT-1 facilitates cell growth, migration and invasion in pancreatic cancer. Oncol Rep. 2014;32(6):2485–92. doi:10.3892/or.2014.3518.PubMed

14.

Pang EJ, Yang R, Fu XB, Liu YF. Overexpression of long non-coding RNA MALAT1 is correlated with clinical progression and unfavorable prognosis in pancreatic cancer. Tumour Biol. 2015;36(4):2403–7. doi:10.1007/s13277-014-2850-8.CrossRefPubMed

15.

Yuan JH, Yang F, Wang F, Ma JZ, Guo YJ, Tao QF, et al. A long noncoding RNA activated by TGF-β promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell. 2014;25(5):666–81. doi:10.1016/j.ccr.2014.03.010.CrossRefPubMed

16.

Saito T, Kurashige J, Nambara S, Komatsu H, Hirata H, Ueda M, et al. A long non-coding RNA activated by transforming growth factor-β is an independent prognostic marker of gastric cancer. Ann Surg Oncol. 2015. doi:10.1245/s10434-015-4554-8.

17.

Iguchi T, Uchi R, Nambara S, Saito T, Komatsu H, Hirata H, et al. A long noncoding RNA, lncRNA-ATB, is involved in the progression and prognosis of colorectal cancer. Anticancer Res. 2015;35(3):1385–8.PubMed

18.

Qu S, Song W, Yang X, Wang J, Zhang R, Zhang Z, et al. Microarray expression profile of circular RNAs in human pancreatic ductal adenocarcinoma. Genomics Data. 2015;5:385–7.CrossRefPubMedPubMedCentral

19.

Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12(12):861–74. doi:10.1038/nrg3074.CrossRefPubMed

20.

Qu S, Yang X, Li X, Wang J, Gao Y, Shang R, et al. Circular RNA: a new star of noncoding RNAs. Cancer Lett. 2015;365(2):141–8. doi:10.1016/j.canlet.2015.06.003.CrossRefPubMed

21.

Kung JT, Colognori D, Lee JT. Long noncoding RNAs: past, present, and future. Genetics. 2013;193(3):651–69. doi:10.1534/genetics.112.146704.CrossRefPubMedPubMedCentral

22.

Shi SJ, Wang LJ, Yu B, Li YH, Jin Y, Bai XZ. LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer. Oncotarget. 2015;6(13):11652–63.CrossRefPubMedPubMedCentral

23.

Yang X, Wang J, Qu S, Zhang H, Ruan B, Gao Y, et al. MicroRNA-200a suppresses metastatic potential of side population cells in human hepatocellular carcinoma by decreasing ZEB2. Oncotarget. 2015;6(10):7918–29.CrossRefPubMedPubMedCentral

24.

Lu R, Ji Z, Li X, Qin J, Cui G, Chen J, et al. Tumor suppressive microRNA-200a inhibits renal cell carcinoma development by directly targeting TGFB2. Tumour Biol. 2015 Mar 27. doi:10.1007/s13277-015-3355-9.

25.

Xia H, Ng SS, Jiang S, Cheung WK, Sze J, Bian XW, et al. miR-200a-mediated down regulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell growth, migration and invasion. Biochem Biophys Res Commun. 2010;391(1):535–41. doi:10.1016/j.bbrc.2009.11.093.CrossRefPubMed

26.

Liu N, Zhong L, Zeng J, Zhang X, Yang Q, Liao D, et al. Up regulation of microRNA-200a associates with tumor proliferation, CSCs phenotype and chemosensitivity in ovarian cancer. Neoplasma. 2015;62(4):550–9. doi:10.4149/neo_2015_066.CrossRefPubMed

27.

Snowdon J, Zhang X, Childs T, Tron VA, Feilotter H. The microRNA-200 family is upregulated in endometrial carcinoma. PLoS One. 2011;6(8):e22828. doi:10.1371/journal.pone.0022828.CrossRefPubMedPubMedCentral

28.

Li A, Omura N, Hong SM, Vincent A, Walter K, Griffith M, et al. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res. 2010;70(13):5226–37.CrossRefPubMedPubMedCentral

Titel: Downregulation of lncRNA-ATB correlates with clinical progression and unfavorable prognosis in pancreatic cancer
verfasst von: Shibin Qu
Xisheng Yang
Wenjie Song
Wei Sun
Xiaolei Li
Jianlin Wang
Yue Zhong
Runze Shang
Bai Ruan
Zhuochao Zhang
Xuan Zhang
Haimin Li
Publikationsdatum: 19.10.2015
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 3/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-4252-y

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Downregulation of lncRNA-ATB correlates with clinical progression and unfavorable prognosis in pancreatic cancer

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2016

Deregulation of miR-93 and miR-143 in human esophageal cancer

XPC (A2920C), XPF (T30028C), TP53 (Arg72Pro), and GSTP1 (Ile105Val) polymorphisms in prognosis of cutaneous melanoma

Decreased expression of p27 is associated with malignant transformation and extrathyroidal extension in papillary thyroid carcinoma

Plasma miR-940 may serve as a novel biomarker for gastric cancer

BMP10 inhibited the growth and migration of gastric cancer cells

CCL18/PITPNM3 enhances migration, invasion, and EMT through the NF-κB signaling pathway in hepatocellular carcinoma

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie